OBJECTIVE: Biliary atresia (BA) frequently results in portal hypertension (PHT), complications of which lead to significant morbidity and mortality. The Childhood Liver Disease Research and Education Network was used to perform a cross-sectional multicentered analysis of PHT in children with BA. METHODS: Subjects with BA receiving medical management at a Childhood Liver Disease Research and Education Network site were enrolled. A priori, clinically evident PHT was defined as "definite" when there was either history of a complication of PHT or clinical findings consistent with PHT (both splenomegaly and thrombocytopenia). PHT was denoted as "possible" if one of the findings was present in the absence of a complication, whereas PHT was "absent" if none of the criteria were met. RESULTS: A total of 163 subjects were enrolled between May 2006 and December 2009. At baseline, definite PHT was present in 49%, possible in 17%, and absent in 34% of subjects. Demographics, growth, and anthropometrics were similar amongst the 3 PHT categories. Alanine aminotransferase, γ-glutamyl transpeptidase, and sodium levels were similar, whereas there were significant differences in aspartate aminotransferase (AST), AST/alanine aminotransferase, albumin, total bilirubin, prothrombin time, white blood cell count, platelet count, and AST/platelet count between definite and absent PHT. Thirty-four percent of those with definite PHT had either prothrombin time >15 seconds or albumin <3 g/dL. CONCLUSIONS: Clinically definable PHT is present in two-thirds of North American long-term BA survivors with their native livers. The presence of PHT is associated with measures of hepatic injury and dysfunction, although in this selected cohort, the degree of hepatic dysfunction is relatively mild and growth is preserved.
OBJECTIVE:Biliary atresia (BA) frequently results in portal hypertension (PHT), complications of which lead to significant morbidity and mortality. The Childhood Liver Disease Research and Education Network was used to perform a cross-sectional multicentered analysis of PHT in children with BA. METHODS: Subjects with BA receiving medical management at a Childhood Liver Disease Research and Education Network site were enrolled. A priori, clinically evident PHT was defined as "definite" when there was either history of a complication of PHT or clinical findings consistent with PHT (both splenomegaly and thrombocytopenia). PHT was denoted as "possible" if one of the findings was present in the absence of a complication, whereas PHT was "absent" if none of the criteria were met. RESULTS: A total of 163 subjects were enrolled between May 2006 and December 2009. At baseline, definite PHT was present in 49%, possible in 17%, and absent in 34% of subjects. Demographics, growth, and anthropometrics were similar amongst the 3 PHT categories. Alanine aminotransferase, γ-glutamyl transpeptidase, and sodium levels were similar, whereas there were significant differences in aspartate aminotransferase (AST), AST/alanine aminotransferase, albumin, total bilirubin, prothrombin time, white blood cell count, platelet count, and AST/platelet count between definite and absent PHT. Thirty-four percent of those with definite PHT had either prothrombin time >15 seconds or albumin <3 g/dL. CONCLUSIONS: Clinically definable PHT is present in two-thirds of North American long-term BA survivors with their native livers. The presence of PHT is associated with measures of hepatic injury and dysfunction, although in this selected cohort, the degree of hepatic dysfunction is relatively mild and growth is preserved.
Authors: Benjamin Shneider; Sukru Emre; Roberto Groszmann; John Karani; Patrick McKiernan; Shiv Sarin; Harohalli Shashidhar; Robert Squires; Riccardo Superina; Jean de Ville de Goyet; Roberto de Franchis Journal: Pediatr Transplant Date: 2006-12
Authors: Kathleen M Loomes; Cathie Spino; Nathan P Goodrich; Thomas N Hangartner; Amanda E Marker; James E Heubi; Binita M Kamath; Benjamin L Shneider; Philip Rosenthal; Paula M Hertel; Saul J Karpen; Jean P Molleston; Karen F Murray; Kathleen B Schwarz; Robert H Squires; Jeffrey Teckman; Yumirle P Turmelle; Estella M Alonso; Averell H Sherker; John C Magee; Ronald J Sokol Journal: Hepatology Date: 2018-12-27 Impact factor: 17.425
Authors: Anna Strongin; Theo Heller; Dan Doherty; Ian A Glass; Melissa A Parisi; Joy Bryant; Peter Choyke; Baris Turkbey; Kailash Daryanani; Deniz Yildirimli; Meghana Vemulapalli; Jim C Mullikin; May C Malicdan; Thierry Vilboux; William A Gahl; Meral Gunay-Aygun Journal: J Pediatr Gastroenterol Nutr Date: 2018-03 Impact factor: 2.839
Authors: Ellen A Tsai; Christopher M Grochowski; Kathleen M Loomes; Kazuhiko Bessho; Hakon Hakonarson; Jorge A Bezerra; Pierre A Russo; Barbara A Haber; Nancy B Spinner; Marcella Devoto Journal: Hum Genet Date: 2013-10-09 Impact factor: 4.132
Authors: Vicky Lee Ng; Barbara H Haber; John C Magee; Alexander Miethke; Karen F Murray; Sonia Michail; Saul J Karpen; Nanda Kerkar; Jean P Molleston; Rene Romero; Philip Rosenthal; Kathleen B Schwarz; Benjamin L Shneider; Yumirle P Turmelle; Estella M Alonso; Averell H Sherker; Ronald J Sokol Journal: J Pediatr Date: 2014-07-09 Impact factor: 4.406